<DOC>
	<DOCNO>NCT01763021</DOCNO>
	<brief_summary>The purpose study assess potential effect rifampin pharmacokinetics ( drug concentration change time ) PCI-32765 healthy participant .</brief_summary>
	<brief_title>A Study Assess Effect Rifampin Pharmacokinetics PCI-32765 Healthy Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single center ( study conduct one site ) , sequential study ( design single group participant administer one study medication sequence ) evaluate potential effect rifampin pharmacokinetics PCI-32765 healthy participants.The study consist 3 phase : screening phase ( 21 day prior first dose study medication ) , treatment phase ( 14 day ) , follow phase ( 10 12 day last dose study medication ) . In treatment phase , single dose PCI-32765 560 mg administer orally Day 1 Day 11 . Rifampin 600 mg ( 2 X 300 mg ) administer orally Days 4 13 ; follow single dose PCI-32765 Day 11 . Follow continue Day 14 . Safety evaluation adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination monitor throughout study . The duration study approximately 45 day .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Participants healthy basis physical examination , medical history , vital sign , electrocardiogram , result blood biochemistry hematology test urinalysis perform screen Agrees protocoldefined use effective contraception Participants medically significant cardiac disease , hematologic , lipid abnormality , significant pulmonary disease ( bronchospastic respiratory ) , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease infectious disease Abnormal clinical laboratory physical examination vital sign Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen , within 3 day first dose study drug schedule Positive human immunodeficiency virustype 1 ( HIV1 ) HIV2 test hepatitis A , B C infection screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Healthy participant</keyword>
	<keyword>PCI-32765</keyword>
	<keyword>Rifampin</keyword>
	<keyword>PCI-45227</keyword>
	<keyword>CYP3A4</keyword>
</DOC>